A clinical trial to assess Clinflamozyde in Covid 19 patients
Latest Information Update: 27 May 2021
At a glance
- Drugs Clinflamozyde (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors GenEros BioPharma
- 27 May 2021 New trial record
- 21 May 2021 According to GenEros Biopharma media release, FDA has approved Clinflamozyde for clinical trials on COVID-19 patients.
- 21 May 2021 According to GenEros Biopharma media release, this trial will start soon